Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160271 | 0.86 | GRM5 (0.38) | GRM5CYP2C9 | |
| SCHEMBL157685 | 0.77 | GAA (0.47) | TSHRGAAALDH1A1KDM4EOPRD1 | |
| SCHEMBL157684 | 0.77 | GAA (0.47) | TSHRGAAALDH1A1KDM4EOPRD1 | |
| SCHEMBL158950 | 0.76 | GRM5 (0.65) | GRM5CYP2C9SMN1; SMN2 | |
| SCHEMBL158866 | 0.73 | GRM5 (0.44) | TSHRGRM5CYP3A4CYP2C9 | |
| SCHEMBL160278 | 0.72 | GRM5 (0.39) | TSHRGAAALDH1A1KDM4EGRM5 | |
| SCHEMBL13328898 | 0.69 | TSHR (0.45) | TSHRGAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL504967 | 0.67 | GRM5 (0.47) | GRM5CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2588670 | 0.67 | GPR119 (0.47) | ALDH1A1KDM4EGRM5 | |
| SCHEMBL13249786 | 0.67 | TSHR (0.45) | TSHRGAAALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2611298-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031024-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031024-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM1 | TSHR 284/4885GAA 2888/4885ALDH1A1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.